Market Research Logo

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company’s proprietary products include Aristada, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to wholesalers, specialty distributors and specialty pharmacies. The company also has a clinical pipeline of products that address CNS disorders such as multiple sclerosis, schizophrenia, depression and addiction. Alkermes is headquartered in Dublin, Ireland.

Alkermes Plc Key Recent Developments

Mar 22,2019 Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
Feb 14,2019 Alkermes Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
Jan 16,2019 Alkermes announces recipients of 1st annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Alkermes Plc - Key Facts
Alkermes Plc - Key Employees
Alkermes Plc - Key Employee Biographies
Alkermes Plc - Major Products and Services
Alkermes Plc - History
Alkermes Plc - Company Statement
Alkermes Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Alkermes Plc - Business Description
Geographical Segment: Ireland
Performance
Geographical Segment: Rest of world
Performance
Geographical Segment: US
Performance
R&D Overview
Alkermes Plc - Corporate Strategy
Alkermes Plc - SWOT Analysis
SWOT Analysis - Overview
Alkermes Plc - Strengths
Alkermes Plc - Weaknesses
Alkermes Plc - Opportunities
Alkermes Plc - Threats
Alkermes Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Alkermes Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 22, 2019: Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
Feb 14, 2019: Alkermes Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
Jan 16, 2019: Alkermes announces recipients of 1st annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
Nov 30, 2018: Statement by Richard Pops, Chairman and CEO of Alkermes on the annual CDC report on Drug Overdose deaths and suicide mortality in the United States
Nov 29, 2018: Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
Oct 29, 2018: Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry
Oct 26, 2018: Alkermes announces recipients of 3rd Annual ALKERMES INSPIRATION GRANTS
Oct 26, 2018: Alkermes announces recipients of 3rd Annual ALKERMES INSPIRATION GRANTS
Oct 23, 2018: Alkermes announces third quarter 2018 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Alkermes Plc, Key Facts
Alkermes Plc, Key Employees
Alkermes Plc, Key Employee Biographies
Alkermes Plc, Major Products and Services
Alkermes Plc, History
Alkermes Plc, Other Locations
Alkermes Plc, Subsidiaries
Alkermes Plc, Key Competitors
Alkermes Plc, Ratios based on current share price
Alkermes Plc, Annual Ratios
Alkermes Plc, Annual Ratios (Cont...1)
Alkermes Plc, Annual Ratios (Cont...2)
Alkermes Plc, Interim Ratios
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Alkermes Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Alkermes Plc, Performance Chart (2014 - 2018)
Alkermes Plc, Ratio Charts
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report